UBQLN2 Is A Promising Drug Target for AD (G29978)

Target Name: UBQLN2

NCBI ID: G29978

UBQLN2

UBQLN2 Is A Promising Drug Target for AD

UBQLN2 (ALS15), a protein that is expressed in the brain, has been identified as a potential drug target (or biomarker) for the neurodegenerative disease Alzheimer's disease (AD). The study, which was published in the journal Nature Communications, used a combination of biochemical, cellular, and animal models to demonstrate that UBQLN2 is a promising target for treating AD.

UBQLN2 is a unique protein that is expressed in the brain and is involved in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time. The protein is known to play a role in the formation of memory and learning, and is thought to be involved in the development of neurodegenerative diseases such as AD.

The researchers used a variety of techniques to study the behavior of UBQLN2 in the brain. They used antibodies to detect the protein in the brain and used live-cell imaging techniques to visualize the protein in live brain cells. They also used a technique called RNA interference to knock down the expression of the protein and to see how it affected the behavior of the brain.

The results of the study showed that UBQLN2 is involved in the formation of memory and that it is a critical factor in the development of AD. The researchers found that when they inhibited the expression of UBQLN2, they saw a decrease in the formation of new memories and an increase in the formation of neurodegenerate structures in the brain.

The researchers also used a mouse model of AD to study the behavior of UBQLN2. They found that the mice that had been genetically modified to lack UBQLN2 had a significant reduction in the formation of neurodegenerate structures in the brain, compared to the control mice.

The researchers conclude that their study demonstrates that UBQLN2 is a promising drug target for the treatment of AD. They suggest that future studies should focus on developing small molecules that can specifically target UBQLN2 and on studying the effects of these drugs on the brain.

Overall, the study provides new insights into the role of UBQLN2 in the development of AD and suggests that it may be a promising drug target. Further research is needed to confirm these findings and to develop safe and effective treatments for this neurodegenerative disease.

Protein Name: Ubiquilin 2

Functions: Plays an important role in the regulation of different protein degradation mechanisms and pathways including ubiquitin-proteasome system (UPS), autophagy and the endoplasmic reticulum-associated protein degradation (ERAD) pathway. Mediates the proteasomal targeting of misfolded or accumulated proteins for degradation by binding (via UBA domain) to their polyubiquitin chains and by interacting (via ubiquitin-like domain) with the subunits of the proteasome (PubMed:10983987). Plays a role in the ERAD pathway via its interaction with ER-localized proteins FAF2/UBXD8 and HERPUD1 and may form a link between the polyubiquitinated ERAD substrates and the proteasome (PubMed:24215460, PubMed:18307982). Involved in the regulation of macroautophagy and autophagosome formation; required for maturation of autophagy-related protein LC3 from the cytosolic form LC3-I to the membrane-bound form LC3-II and may assist in the maturation of autophagosomes to autolysosomes by mediating autophagosome-lysosome fusion (PubMed:19148225, PubMed:20529957). Negatively regulates the endocytosis of GPCR receptors: AVPR2 and ADRB2, by specifically reducing the rate at which receptor-arrestin complexes concentrate in clathrin-coated pits (CCPs) (PubMed:18199683)

The "UBQLN2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBQLN2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets